
Upgrades
According to Stifel, the prior rating for Clearside Biomedical Inc (NASDAQ:CLSD) was changed from Hold to Buy. In the third quarter, Clearside Biomedical showed an EPS of $0.13, compared to $0.08 from the year-ago quarter. The current stock performance of Clearside Biomedical shows a 52-week-high of $2.95 and a 52-week-low of $1.00. Moreover, at the end of the last trading period, the closing price was at $1.28.